These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study. Gray GE; Moodie Z; Metch B; Gilbert PB; Bekker LG; Churchyard G; Nchabeleng M; Mlisana K; Laher F; Roux S; Mngadi K; Innes C; Mathebula M; Allen M; McElrath MJ; Robertson M; Kublin J; Corey L; Lancet Infect Dis; 2014 May; 14(5):388-96. PubMed ID: 24560541 [TBL] [Abstract][Full Text] [Related]
3. Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine. Gray G; Buchbinder S; Duerr A Curr Opin HIV AIDS; 2010 Sep; 5(5):357-61. PubMed ID: 20978374 [TBL] [Abstract][Full Text] [Related]
4. A study of vaccine-induced immune pressure on breakthrough infections in the Phambili phase 2b HIV-1 vaccine efficacy trial. Hertz T; Logan MG; Rolland M; Magaret CA; Rademeyer C; Fiore-Gartland A; Edlefsen PT; DeCamp A; Ahmed H; Ngandu N; Larsen BB; Frahm N; Marais J; Thebus R; Geraghty D; Hural J; Corey L; Kublin J; Gray G; McElrath MJ; Mullins JI; Gilbert PB; Williamson C Vaccine; 2016 Nov; 34(47):5792-5801. PubMed ID: 27756485 [TBL] [Abstract][Full Text] [Related]
5. Novel Adenovirus type 5 vaccine platform induces cellular immunity against HIV-1 Gag, Pol, Nef despite the presence of Ad5 immunity. Gabitzsch ES; Xu Y; Yoshida LH; Balint J; Amalfitano A; Jones FR Vaccine; 2009 Oct; 27(46):6394-8. PubMed ID: 19559110 [TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of the Merck adenovirus serotype 5 (MRKAd5) and MRKAd6 human immunodeficiency virus type 1 trigene vaccines alone and in combination in healthy adults. Harro C; Sun X; Stek JE; Leavitt RY; Mehrotra DV; Wang F; Bett AJ; Casimiro DR; Shiver JW; DiNubile MJ; Quirk E; Clin Vaccine Immunol; 2009 Sep; 16(9):1285-92. PubMed ID: 19605598 [TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. Gray GE; Allen M; Moodie Z; Churchyard G; Bekker LG; Nchabeleng M; Mlisana K; Metch B; de Bruyn G; Latka MH; Roux S; Mathebula M; Naicker N; Ducar C; Carter DK; Puren A; Eaton N; McElrath MJ; Robertson M; Corey L; Kublin JG; Lancet Infect Dis; 2011 Jul; 11(7):507-15. PubMed ID: 21570355 [TBL] [Abstract][Full Text] [Related]
8. A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204). Churchyard GJ; Morgan C; Adams E; Hural J; Graham BS; Moodie Z; Grove D; Gray G; Bekker LG; McElrath MJ; Tomaras GD; Goepfert P; Kalams S; Baden LR; Lally M; Dolin R; Blattner W; Kalichman A; Figueroa JP; Pape J; Schechter M; Defawe O; De Rosa SC; Montefiori DC; Nabel GJ; Corey L; Keefer MC; PLoS One; 2011; 6(8):e21225. PubMed ID: 21857901 [TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa. Jaoko W; Karita E; Kayitenkore K; Omosa-Manyonyi G; Allen S; Than S; Adams EM; Graham BS; Koup RA; Bailer RT; Smith C; Dally L; Farah B; Anzala O; Muvunyi CM; Bizimana J; Tarragona-Fiol T; Bergin PJ; Hayes P; Ho M; Loughran K; Komaroff W; Stevens G; Thomson H; Boaz MJ; Cox JH; Schmidt C; Gilmour J; Nabel GJ; Fast P; Bwayo J PLoS One; 2010 Sep; 5(9):e12873. PubMed ID: 20877623 [TBL] [Abstract][Full Text] [Related]
10. Immune-correlates analysis of an HIV-1 vaccine efficacy trial reveals an association of nonspecific interferon-γ secretion with increased HIV-1 infection risk: a cohort-based modeling study. Huang Y; Duerr A; Frahm N; Zhang L; Moodie Z; De Rosa S; McElrath MJ; Gilbert PB PLoS One; 2014; 9(11):e108631. PubMed ID: 25369172 [TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. Priddy FH; Brown D; Kublin J; Monahan K; Wright DP; Lalezari J; Santiago S; Marmor M; Lally M; Novak RM; Brown SJ; Kulkarni P; Dubey SA; Kierstead LS; Casimiro DR; Mogg R; DiNubile MJ; Shiver JW; Leavitt RY; Robertson MN; Mehrotra DV; Quirk E; Clin Infect Dis; 2008 Jun; 46(11):1769-81. PubMed ID: 18433307 [TBL] [Abstract][Full Text] [Related]
12. Analysis of T cell responses to chimpanzee adenovirus vectors encoding HIV gag-pol-nef antigen. Herath S; Le Heron A; Colloca S; Bergin P; Patterson S; Weber J; Tatoud R; Dickson G Vaccine; 2015 Dec; 33(51):7283-7289. PubMed ID: 26546736 [TBL] [Abstract][Full Text] [Related]
16. Low-dose penile SIVmac251 exposure of rhesus macaques infected with adenovirus type 5 (Ad5) and then immunized with a replication-defective Ad5-based SIV gag/pol/nef vaccine recapitulates the results of the phase IIb step trial of a similar HIV-1 vaccine. Qureshi H; Ma ZM; Huang Y; Hodge G; Thomas MA; DiPasquale J; DeSilva V; Fritts L; Bett AJ; Casimiro DR; Shiver JW; Robert-Guroff M; Robertson MN; McChesney MB; Gilbert PB; Miller CJ J Virol; 2012 Feb; 86(4):2239-50. PubMed ID: 22156519 [TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1. Mothe B; Climent N; Plana M; Rosàs M; Jiménez JL; Muñoz-Fernández MÁ; Puertas MC; Carrillo J; Gonzalez N; León A; Pich J; Arnaiz JA; Gatell JM; Clotet B; Blanco J; Alcamí J; Martinez-Picado J; Alvarez-Fernández C; Sánchez-Palomino S; Guardo AC; Peña J; Benito JM; Rallón N; Gómez CE; Perdiguero B; García-Arriaza J; Esteban M; López Bernaldo de Quirós JC; Brander C; García F; J Antimicrob Chemother; 2015; 70(6):1833-42. PubMed ID: 25724985 [TBL] [Abstract][Full Text] [Related]
18. Multi-layered Gag-specific immunodominant responses contribute to improved viral control in the CRF01_AE subtype of HIV-1-infected MSM subjects. Jiang F; Han X; Zhang H; Zhao B; An M; Xu J; Chu Z; Dong T; Shang H BMC Immunol; 2016 Aug; 17(1):28. PubMed ID: 27577610 [TBL] [Abstract][Full Text] [Related]
19. Phambili: moving forward without the blindfold. Michael NL; Robb ML Lancet Infect Dis; 2014 May; 14(5):361-2. PubMed ID: 24560542 [No Abstract] [Full Text] [Related]
20. Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials. Huang Y; Follmann D; Nason M; Zhang L; Huang Y; Mehrotra DV; Moodie Z; Metch B; Janes H; Keefer MC; Churchyard G; Robb ML; Fast PE; Duerr A; McElrath MJ; Corey L; Mascola JR; Graham BS; Sobieszczyk ME; Kublin JG; Robertson M; Hammer SM; Gray GE; Buchbinder SP; Gilbert PB PLoS One; 2015; 10(9):e0136626. PubMed ID: 26332672 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]